Safety and Efficacy of Bimatoprost Solution 0 Safety and Efficacy of Bimatoprost Solution 0.03% Topical Application in Patients with Chemotherapy-Induced Eyelash Loss  Gurpreet S. Ahluwalia  Journal of Investigative Dermatology Symposium Proceedings  Volume 16, Issue 1, Pages S73-S76 (December 2013) DOI: 10.1038/jidsymp.2013.30 Copyright © 2013 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 1 Percent of patients with at least 2-grade improvement from baseline on the Global Eyelash Assessment (GEA) scale. Bim/Bim, group treated with bimatoprost for TP1 and TP2; M, month; TP1, treatment period 1 of 0–6 months; TP2, treatment period 2 of 6–12 months; Veh/Bim, group treated with vehicle during TP1 and with bimatoprost during TP2. Journal of Investigative Dermatology Symposium Proceedings 2013 16, S73-S76DOI: (10.1038/jidsymp.2013.30) Copyright © 2013 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 2 Example of the eyelash profile at baseline and after treatment in postchemotherapy patients. ESQ, Eyelash Satisfaction Questionnaire; GEA, Global Eyelash Assessment. Journal of Investigative Dermatology Symposium Proceedings 2013 16, S73-S76DOI: (10.1038/jidsymp.2013.30) Copyright © 2013 The Society for Investigative Dermatology, Inc Terms and Conditions